Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $160.4 million.

  • Taysha Gene Therapies' Liabilities and Shareholders Equity rose 75.65% to $316.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $948.6 million, marking a year-over-year increase of 34.30%. This contributed to the annual value of $160.4 million for FY2024, which is 7.16% down from last year.
  • Taysha Gene Therapies' Liabilities and Shareholders Equity amounted to $160.4 million in FY2024, which was down 7.16% from $172.7 million recorded in FY2023.
  • Taysha Gene Therapies' Liabilities and Shareholders Equity's 5-year high stood at $172.7 million during FY2023, with a 5-year trough of $126.3 million in FY2022.
  • In the last 3 years, Taysha Gene Therapies' Liabilities and Shareholders Equity had a median value of $160.4 million in 2024 and averaged $153.1 million.
  • In the last 5 years, Taysha Gene Therapies' Liabilities and Shareholders Equity surged by 36.79% in 2023 and then declined by 7.16% in 2024.
  • Taysha Gene Therapies' Liabilities and Shareholders Equity (Yearly) stood at $126.3 million in 2022, then soared by 36.79% to $172.7 million in 2023, then decreased by 7.16% to $160.4 million in 2024.